ReviewCurrent rheumatology reports2026
The Assessment of Disease Activity and Renal Prognosis in AAV - The Contribution of Urinary Biomarkers and Renal Biopsy.
Review in Current rheumatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRenal involvement is a major determinant of morbidity and mortality in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Accurate assessment of disease activity and renal prognosis remains challenging due to the complex interplay between immune-mediated injury and chronic damage. This review summarizes recent advances in understanding the pathogenesis of renal involvement in AAV and the contributions of renal biopsy and urinary biomarkers to disease assessment and outcome prediction. RECENT
findingsCurrent studies have elucidated key mechanisms underlying renal injury in AAV, including endothelial damage, complement pathway amplification, neutrophil activation, and dysregulated immune responses. Although renal biopsy remains the diagnostic gold standard, histopathological classifications and prognostic tools have refined prediction of kidney failure but are limited by sampling variability and invasiveness. AAV-glomerulonephritis activity evaluation still relies on evaluation of kidney function biomarkers (serum creatinine or cystatin-C), along with proteinuria and hematuria. Emerging urinary biomarkers, such as monocyte chemoattractant protein-1 (MCP-1), kidney injury molecule-1 (KIM-1), and soluble CD163, among others, reflect glomerular and tubular injury and show promise for non-invasive disease monitoring. However, heterogeneity in study design, small sample sizes, and lack of standardization limit their clinical application. Integrating histopathological data with urinary biomarkers offers a more precise evaluation of renal activity and chronicity in AAV. Future research should focus on validating biomarker panels in large, longitudinal cohorts and combining them with biopsy findings to develop personalized monitoring and treatment strategies. Such integration may enable early detection of renal relapse, reduce treatment toxicity, and improve long-term outcomes for patients with AAV.
Indexed as
Identifiers
41524926What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.